Flaherty M L, Tao H, Haverbusch M, Sekar P, Kleindorfer D, Kissela B, Khatri P, Stettler B, Adeoye O, Moomaw C J, Broderick J P, Woo D
Department of Neurology, University of Cincinnati Academic Health Center, Cincinnati, OH 45267-0525, USA.
Neurology. 2008 Sep 30;71(14):1084-9. doi: 10.1212/01.wnl.0000326895.58992.27.
Among patients with intracerebral hemorrhage (ICH), warfarin use before onset leads to greater mortality. In a retrospective study, we sought to determine whether warfarin use is associated with larger initial hematoma volume, one determinant of mortality after ICH.
We identified all patients hospitalized with ICH in the Greater Cincinnati region from January through December 2005. ICH volumes were measured on the first available brain scan by using the abc/2 method. Univariable analyses and a multivariable generalized linear model were used to determine whether international normalized ratio (INR) influenced initial ICH volume after adjusting for other factors, including age, race, sex, antiplatelet use, hemorrhage location, and time from stroke onset to scan.
There were 258 patients with ICH, including 51 patients taking warfarin. In univariable comparison, when INR was stratified, there was a trend toward a difference in hematoma volume by INR category (INR <1.2, 13.4 mL; INR 1.2-2.0, 9.3 mL; INR 2.1-3.0, 14.0 mL; INR >3.0, 33.2 mL; p = 0.10). In the model, compared with patients with INR <1.2, there was no difference in hematoma size for patients with INR 1.2-2.0 (p = 0.25) or INR 2.1-3.0 (p = 0.36), but patients with INR >3.0 had greater hematoma volume (p = 0.02). Other predictors of larger hematoma size were ICH location (lobar compared with deep cerebral, p = 0.02) and shorter time from stroke onset to scan (p < 0.001).
Warfarin use was associated with larger initial intracerebral hemorrhage (ICH) volume, but this effect was only observed for INR values >3.0. Larger ICH volume among warfarin users likely accounts for part of the excess mortality in this group.
在脑出血(ICH)患者中,发病前使用华法林会导致更高的死亡率。在一项回顾性研究中,我们试图确定使用华法林是否与更大的初始血肿体积相关,初始血肿体积是脑出血后死亡率的一个决定因素。
我们确定了2005年1月至12月在大辛辛那提地区因脑出血住院的所有患者。通过abc/2方法在首次获得的脑部扫描上测量脑出血体积。使用单变量分析和多变量广义线性模型来确定在调整其他因素(包括年龄、种族、性别、抗血小板药物使用、出血部位以及从中风发作到扫描的时间)后,国际标准化比值(INR)是否会影响初始脑出血体积。
有258例脑出血患者,其中51例服用华法林。在单变量比较中,当对INR进行分层时,按INR类别血肿体积存在差异趋势(INR<1.2,13.4 mL;INR 1.2 - 2.0,9.3 mL;INR 2.1 - 3.0,14.0 mL;INR>3.0,33.2 mL;p = 0.10)。在模型中,与INR<1.2的患者相比,INR 1.2 - 2.0(p = 0.25)或INR 2.1 - 3.0(p = 0.36)的患者血肿大小无差异,但INR>3.0的患者血肿体积更大(p = 0.02)。血肿体积更大的其他预测因素是脑出血部位(脑叶出血与深部脑出血相比,p = 0.02)以及从中风发作到扫描的时间更短(p<0.001)。
使用华法林与更大的初始脑出血(ICH)体积相关,但这种效应仅在INR值>3.0时观察到。华法林使用者中更大的脑出血体积可能是该组额外死亡率的部分原因。